144 related articles for article (PubMed ID: 24807458)
1. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
Tsakalozou E; Adane ED; Liang Y; Arnold SM; Leggas M
Cancer Chemother Pharmacol; 2014 Jul; 74(1):45-54. PubMed ID: 24807458
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.
Arnold SM; Rinehart JJ; Tsakalozou E; Eckardt JR; Fields SZ; Shelton BJ; DeSimone PA; Kee BK; Moscow JA; Leggas M
Clin Cancer Res; 2010 Jan; 16(2):673-80. PubMed ID: 20068096
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
Schluep T; Hwang J; Cheng J; Heidel JD; Bartlett DW; Hollister B; Davis ME
Clin Cancer Res; 2006 Mar; 12(5):1606-14. PubMed ID: 16533788
[TBL] [Abstract][Full Text] [Related]
6. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Garrison MA; Hammond LA; Geyer CE; Schwartz G; Tolcher AW; Smetzer L; Figueroa JA; Ducharme M; Coyle J; Takimoto CH; De Jager RL; Rowinsky EK
Clin Cancer Res; 2003 Jul; 9(7):2527-37. PubMed ID: 12855627
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Rhee CK; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim CH; Shim BY; Kim HK; Sun DS; Kim KH
Lung Cancer; 2011 Apr; 72(1):64-7. PubMed ID: 20832894
[TBL] [Abstract][Full Text] [Related]
8. The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.
Bence AK; Mattingly CA; Burke TG; Adams VR
Cancer Chemother Pharmacol; 2004 Oct; 54(4):354-60. PubMed ID: 15197485
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91.
Yeh TK; Li CM; Chen CP; Chuu JJ; Huang CL; Wang HS; Shen CC; Lee TY; Chang CY; Chang CM; Chao YS; Lin CT; Chang JY; Chen CT
Pharmacol Res; 2010 Feb; 61(2):108-15. PubMed ID: 19643180
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
11. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
[TBL] [Abstract][Full Text] [Related]
12. The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
Lopez-Barcons LA; Zhang J; Siriwitayawan G; Burke TG; Perez-Soler R
Neoplasia; 2004; 6(5):457-67. PubMed ID: 15548354
[TBL] [Abstract][Full Text] [Related]
13. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
[TBL] [Abstract][Full Text] [Related]
14. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Joerger M; Hess D; Delmonte A; Gallerani E; Fasolo A; Gianni L; Cresta S; Barbieri P; Pace S; Sessa C
Br J Clin Pharmacol; 2015 Jul; 80(1):128-38. PubMed ID: 25580946
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer.
Yeo CD; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim KH; Shim BY; Kim CH
Cancer Chemother Pharmacol; 2013 Oct; 72(4):809-14. PubMed ID: 23918044
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
18. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
[TBL] [Abstract][Full Text] [Related]
19. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]